Sanofi (SNY) wins FDA label expansion for its MenQuadfi meningococcal vaccine for use in infants as young as six weeks. Read ...

HHS Secretary Robert F. Kennedy Jr. threatened to bar NIH scientists from publishing in leading medical journals, saying the ...

The U.S. FDA has approved an expanded indication for Sanofi (NASDAQ:SNY)’s quadrivalent meningococcal vaccine, MenQuadfi, now ...

French drugmaker Sanofi said the U.S. Food and Drug Administration has approved its meningococcal vaccine for use in infants ...

The federal agency provided BioCryst Pharmaceuticals a target action date of September 12, 2025 for potential approval of berotralstat (ORLADEYO). On May 14, 2025, the FDA accepted a new drug ...

Meanwhile, flu vaccines—anchored by deep public-sector distribution—generated €2.25 billion, and MenQuadfi, a meningitis vaccine, posted 50.5% growth. Despite some expected erosion in older ...

In a May 7, 2025 announcement, Infinant Health stated that its investigational drug candidate INF108 received both orphan drug and rare pediatric disease designations for the prevention of necrotizing ...

Sanofi Eyes Extension of Meningococcal Disease Shot to Infants, Toddlers Sanofi’s meningococcal disease vaccine MenQuadfi is currently approved for the primary immunization of children aged two years ...